Evidence map›Paper›PMID 40401434›Full record

ArticleBiotechnology progress

Minimizing batch-to-batch variability of a live virus vaccine by process analytical technologies.

Katherine Forrester, Thomas R Blanda, Marena Trauger, Rachel Thompson, Neil Templeton

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Katherine ForresterProcess Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Thomas R BlandaProcess Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Marena TraugerProcess Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Rachel ThompsonAnalytical Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Neil TempletonProcess Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0001-7423-4422

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For bioprocesses producing live virus, such as enterovirus Coxsackievirus A21, viral titer (infectivity basis) decay rates can exceed 30% within a day. Consequently, harvest timing is paramount. To optimize titer at harvest, a continuous viral product titer model was generated to elucidate kinetics. The model leveraged experimentally determined viable cell density, cell-specific viral productivity, and viral specific decay rates. Next, three separate online process analytical technology (PAT) harvest triggers were developed to predict maximal viral titer. Finally, the PAT harvest triggers were tested alongside traditional time-based harvests. The harvest triggers utilized common bioprocessing tools - dissolved oxygen (DO) and capacitance probes - to track DO and viable cell volume (VCV) and derived a third parameter, cell-specific oxygen uptake rate. Harvesting with PAT triggers allowed for significantly improved batch-to-batch consistency. The standard deviation of harvest yield was reduced by 41% (DO), 56% (OUR) and 71% (capacitance) as compared to the industry standard time-based harvest. Even when a process deviation in inoculated cell density occurred, causing a significant shift in viral titer kinetics, the PAT harvest triggers yielded greater than 87% of peak titer. By comparison, the time-based harvest yielded 16%.

Indexed as

Batch Cell Culture TechniquesEnterovirusViral VaccinesAnimalsBioreactorsCricetulusKineticsOxygenOxygenViral Vaccinesbioprocessbioreactorcapacitancedissolved oxygenharvestlytic virusmammalian cell culturemicrocarrieroxygen uptake rate

Identifiers

PMID40401434
PMCPMC12531925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.